Camilo Serrano, MD
Psychiatry · Carneys Point, NJNPI 1780744250
Payments from drug & device makers
Across 492 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$909
- Otsuka America Pharmaceutical, Inc.$790
- Neurocrine Biosciences, Inc.$685
- Teva Pharmaceuticals USA, Inc.$605
- Alkermes, Inc.$512
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,10397%
- Education$1873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 56 | $1,296 |
| AbbVie(2 entities) | 102 | $909 |
| Otsuka America Pharmaceutical, Inc. | 56 | $790 |
| Neurocrine Biosciences, Inc. | 44 | $685 |
| Teva Pharmaceuticals USA, Inc. | 38 | $605 |
| Alkermes, Inc. | 34 | $512 |
| Johnson & Johnson | 24 | $393 |
| Axsome Therapeutics, Inc. | 13 | $265 |
| Vanda Pharmaceuticals Inc. | 17 | $258 |
| Corium, LLC | 15 | $229 |
| E.r. Squibb & Sons, L.L.C. | 15 | $226 |
| Sunovion Pharmaceuticals Inc. | 14 | $196 |
| Almatica Pharma LLC | 12 | $187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $155 |
| Lundbeck LLC | 11 | $151 |
| Supernus Pharmaceuticals, Inc. | 8 | $130 |
| Ironshore Pharmaceuticals Inc. | 5 | $69 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Avanir Pharmaceuticals, Inc. | 3 | $39 |
| Eisai Inc. | 2 | $28 |
| Merck | 2 | $27 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Neuronetics, Inc. | 2 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Indivior Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,290 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 100 | $147,257 |
| RexultiBrexpiprazole | 63 | $91,578 |
| Abilify AsimtufiiAripiprazole | 11 | $63,936 |
| AtivanLorazepam | 13 | $57,908 |
| TrintellixVortioxetine Hydrobromide | 67 | $32,835 |
| Seroquel XrQuetiapine Fumarate | 36 | $30,827 |
| CaplytaLumateperone Tosylate | 19 | $30,715 |
| ZyprexaOlanzapine | 13 | $26,873 |
| Lurasidone Hcl | 64 | $26,172 |
| Aripiprazole | 219 | $18,452 |
| ZoloftSertraline Hcl | 28 | $17,977 |
| BelsomraSuvorexant | 30 | $15,305 |
| FetzimaLevomilnacipran Hcl | 29 | $14,428 |
| QuviviqDaridorexant Hcl | 26 | $13,008 |
| Sertraline Hcl | 226 | $11,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $909 | $161,685129 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii | $790 | $155,51474 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $155 | $32,83567 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,296 | $30,71519 claims |
| MerckBelsomra | $27 | $15,30530 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $63 | $13,00826 claims |
| Almatica Pharma LLCSertraline Hcl | $187 | $11,367226 claims |
| Johnson & JohnsonConcerta | $393 | $4,55913 claims |
| Corium, LLCAzstarys | $229 | $4,22111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Carneys Point
- Leon RosenbergCherry Hill$6.4M
- Steven GlassClementon$3.9M
- Judith JosephPaterson$3.8M
- Jeffrey ApterPrinceton$1.7M
- Roberta BallCherry Hill$741K
- Marc CantillonLivingston$524K
- Sanjay VarmaPrinceton$479K
- Manuel SanchezNewark$474K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.